Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection☆
Introduction
Congenital cytomegalovirus (cCMV) infection occurs when virus from the mother crosses the placenta and infects the immunologically immature fetus, as a result of primary maternal infection, reinfection or reactivation. The consequences of cCMV infection include fetal or infant death or neurological and sensory impairments [1], [2]. Children with cCMV-related disabilities may require extensive medical care, special education services, and interventions. Costs associated with cCMV infections in the United States were estimated in the 1990s to be at least $1.9 billion annually [3]. Population-based epidemiological data are needed to update and provide more complete estimates of the full spectrum of disease and related disabilities caused by cCMV [4]. Because of the burden associated with cCMV disease, a CMV vaccine was rated as a “highest priority” for vaccine development by the Institute of Medicine in the United States [3], [5]. Several CMV vaccines have been evaluated in clinical trials, although none is yet close to licensure [6].
Mathematical modeling has become increasingly useful for investigating the dynamics of infection and potential impact of vaccination and identifying critical knowledge gaps for study [7]. Identifying which populations to target for CMV vaccination that would result in greatest reductions in the burden of cCMV disease may provide additional insight for the development and design of future CMV vaccines and clinical trials globally. Understanding how vaccination strategies might need to be tailored to underlying population epidemiology is important because of substantial differences in CMV seroprevalence and proportion of cCMV infections due to primary maternal infection within and between countries. We used mathematical modeling to explore the potential impact of CMV vaccination in the United States, a population with moderate seroprevalence, and in Brazil, a population with high seroprevalence. We estimated the potential impact of vaccination on cCMV infections, overall and by type of maternal infection, both at equilibrium and with respect to time after vaccine introduction.
Section snippets
Methods
We constructed a deterministic, age-specific and time-dependent mathematical model of pathogen transmission, with six groups in our human population: susceptible, primarily infected, latently infected, reactivated/reinfected, susceptible vaccinated (before primary infection), and latently infected vaccinated (after primary infection) (Fig. 1). The system of differential equations describing the model is provided in the supplementary data (Appendix 1).
We defined susceptible as CMV seronegative
R0 and estimated distribution of cCMV infections by type of maternal infection in the pre-vaccine state
Using the NGM method, we estimated an R0 of 1.94 in the United States, and 5.17 in Brazil, similar to those estimated using the ‘constant force of infection’ method (Supplementary data – Appendix 2). Assuming the modified contact mixing matrix pattern III and 20-year latency duration, the model-generated distribution of cCMV infections by type of maternal infection in a pre-vaccine state was 16% from primary maternal infection, 12% from reinfection and 72% from reactivation for the United
Discussion
Using a mathematical model of CMV epidemiology parameterized with data from the United States and Brazil, we assessed the potential impact of vaccination on CMV seroprevalence and cCMV infections. Concurrent vaccination at ages 12–18 months and 15–19 years would have the greatest impact on reducing the number of cCMV infections overall, both in populations with moderate and high baseline maternal seroprevalence. Our model suggests that such a vaccination strategy, assuming a vaccine with 70%
References (28)
- et al.
Mathematical models in the evaluation of health programmes
Lancet
(2011) Human cytomegalovirus: latency and reactivation in the myeloid lineage
J Clin Virol
(2008)- et al.
Desirability and feasibility of a vaccine against cytomegalovirus
Vaccine
(2013) - et al.
Encouraging prospects for immunisation against primary cytomegalovirus infection
Vaccine
(2001) - et al.
Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome
Prenat Diagn
(2001) - et al.
Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality
Pediatr Infect Dis J
(1992) - et al.
Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee
Clin Infect Dis
(2004) - et al.
The economic impact of congenital CMV infection: methods and estimates
Vaccines for the 21st century: a tool for decision making
(2000)Cytomegalovirus vaccine development
Curr Top Microbiol Immunol
(2008)
Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection
Rev Med Virol
Cytomegalovirus reinfections in healthy seroimmune women
J Infect Dis
Maternal immunity and prevention of congenital cytomegalovirus infection
J Am Med Assoc
Modelling immunization strategies with cytomegalovirus vaccine candidates
Epidemiol Infect
Cited by (26)
Vaccine value profile for cytomegalovirus
2023, VaccineModestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level
2022, VaccineCitation Excerpt :Because preschool-aged children appear to be a dominant source of CMV transmission [5–7,11], vaccination of younger age groups may be more effective at reducing the overall CMV prevalence and as a result, lead to fewer cases of cCMV. To determine the optimal CMV vaccination strategy, mathematical models have been developed to describe viral transmission and simulate the use of vaccines with various characteristics, and in different target populations [12,17,25–27]. While some of these models were age-structured [12,17,27], incorporated increased transmission of CMV from mother to infant due to breastfeeding [12,27], or accounted for potential maternal reinfection [12,17], they do not rigorously examine the high risk of transmission from young children to their mothers (e.g., due to diaper changing), or how both infectiousness and immunity against CMV wane with respect to time and the age of the infected individual.
Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies
2021, Seminars in PerinatologyCitation Excerpt :The CEAs of vaccination against CMV likely understated cost-effectiveness by not modeling the indirect impact of vaccine-derived herd immunity on protection to susceptible individuals.90,91 The indirect protective effect of a CMV vaccine is expected to be key to its population-level effectiveness.55,92 N'Diaye et al. acknowledged that this exclusion made their estimates of CMV vaccine cost-effectiveness conservative.72
- ☆
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.